Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA

Eur J Neurol. 2012 Nov;19(11):1421-6. doi: 10.1111/j.1468-1331.2012.03737.x. Epub 2012 Jun 11.

Abstract

Background and purpose: The etiology of stroke in young patients remains undetermined in up to half of the cases. Data on prevalence of Fabry disease (FD) in young people with cryptogenic ischaemic stroke are limited and controversial. We aimed to evaluate the frequency of unrecognized FD in a cohort of stroke patients at a tertiary stroke center.

Methods: Patients suffering from first cryptogenic ischaemic stroke or transient ischaemic attack (TIA) at the age of 18-55 years were screened for the presence of FD. We measured the serum activity of α-galactosidase (α-GAL) in all patients. In addition, sequencing of α-GAL gene was performed in men with low enzyme activity and in all women.

Results: Between January, 2006, and October, 2009, we recruited 150 patients (102 men, 48 women) with a mean age of 43 ± 9 years at symptom onset (135 ischaemic stroke, 15 TIA). The α-GAL activity was low in nine patients (6%; six men and three women). Genetic sequencing in six men with low enzyme activity and all 48 women detected no α-GAL gene mutation.

Conclusion: Our study suggests that the yield of screening for FD in patients with first cryptogenic ischaemic stroke or TIA is very low. Further large-scale studies are needed to investigate the importance of FD amongst patients with recurrent cryptogenic strokes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Fabry Disease / complications*
  • Fabry Disease / epidemiology*
  • Female
  • Humans
  • Ischemic Attack, Transient / etiology*
  • Male
  • Middle Aged
  • Prevalence
  • Stroke / etiology*
  • Switzerland / epidemiology
  • Young Adult
  • alpha-Galactosidase / analysis
  • alpha-Galactosidase / blood
  • alpha-Galactosidase / genetics

Substances

  • GLA protein, human
  • alpha-Galactosidase